Recent Updates
Recently added Catalysts

IMA203

Phase 3

Melanoma, Cutaneous Malignant | Cell Therapies | Oncology |Immatics N.V.|Trials Updated: Oct 30, 2026

IMA203 development status

Highest phase Phase 3
Registered trials 2 across 1 sponsor since Dec 2024

IMA203 target and mechanism

Molecular targetPRAME
ModalityCell Therapies

Also known as IMA203 Product, IMA203 product- flat dose, anzutresgene autoleucel, anzu-cel

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials3
Total Enrollment840

FDA Designations

RMAT

IMA203 clinical trials

IMA203 · 3 trials · 8 indications

Phase 3 1Phase 1/2 1Phase 1 1
NCT06743126SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaMelanoma, Cutaneous Malignant
RECRUITING450 Analytics
PHASE3RECRUITING
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Melanoma, Cutaneous MalignantUnlock trial analytics

Study Endpoints

Primary Endpoints

Progression-free survival assessed by BICR
up to 5 years post first treatment of last patient

progression-free survival (PFS), centrally assessed (by blinded independent central review) using RECIST 1.1

Phase 1: Determine the MTD and/or recommended dose for extension for IMA203/IMA203CD8
28 days

Number of patients with dose-limiting toxicities (DLTs)

Phase 1 and Phase 2: Number and grade of treatment emergent adverse events and adverse events of special interest in subjects treated.
35 days

Treatment emergent adverse events (TEAEs), Adverse events of special interest (AESIs) and Treatment-emergent serious adverse events (TESAEs).

Phase 1 and Phase 2: Tumor Response
5 years

Objective response rate (ORR) based on best overall response (BOR) of complete response (CR) and partial response (PR) centrally assessed (by a BICR1) using RECIST1.1

Number of participants with dose-limiting toxicities (DLTs)
one year post infusion of IMA203

Number of DLTs will be used to determine the maximum tolerated dose (MTD) and/or recommended dose for extension (RDE) after treatment with IMA203 product in combination with mRNA-4203

Number of treatment emergent adverse events (AEs), AEs of special interest, serious AEs (SAEs), changes in laboratory parameters and vital signs, and frequency of dose interruptions, reductions and discontinuations
one year post infusion of IMA203

Used to evaluate safety and tolerability of treatment with IMA203 in combination with mRNA-4203

Secondary Endpoints

Overall survival (OS)
up to 5 years post first treatment of last patient
Objective response rate (ORR)
up to 5 years post first treatment of last patient
Progression-free survival
up to 5 years post first treatment of last patient
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Experimental armEXPERIMENTALNon-myeloablative chemotherapy for lymphodepletion (LD) over 4 days using fludarabine (FLU) and cyclophosphamide (CY), one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy
Control arm- investigator's choiceACTIVE_COMPARATORInvestigator's choice of treatment approved by the respective Competent Authority (nivolumab plus relatlimab \[Opdualag®\], lifileucel, nivolumab, pembrolizumab, ipilimumab, or chemotherapy \[e.g., dacarbazine, temozolomide, paclitaxel, alb-bound paclitaxel, or paclitaxel plus carboplatin\]) as determined by the site investigator in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC), optional bridging therapy.
Dose Escalation A (closed to enrollment)EXPERIMENTALDose escalation of IMA203
Extension Cohort AEXPERIMENTALIMA203 at RP2D
Extension Cohort B (closed to enrollment)EXPERIMENTALIMA203 at RP2D + nivolumab
Extension Cohort AAEXPERIMENTALIMA203 at final RP2D (flat dose)
Uveal MelanomaEXPERIMENTALIMA203 at RP2D
Dose Escalation BEXPERIMENTALDose escalation of IMA203CD8
Extension Cohort CEXPERIMENTALIMA203CD8 at dose levels confirmed to be safe
Extension Cohort DEXPERIMENTALIMA203CD8 at dose levels confirmed to be safe; without IL-2
OvarianEXPERIMENTALIMA203CD8 monotherapy at dose levels confirmed to be safe
EndometrialEXPERIMENTALIMA203CD8 monotherapy at dose levels confirmed to be safe
Head and Neck, Lung, and Triple Negative Breast CancerEXPERIMENTALIMA203CD8 monotherapy at dose levels confirmed to be safe
Rare CancersEXPERIMENTALIMA203CD8 monotherapy at dose levels confirmed to be safe
IMA203 with mRNA-4203 in participants with metastatic cutaneous melanoma or synovial sarcomaEXPERIMENTALThis is a non-comparative, open-label trial with different cohorts investigating IMA203 in combination with mRNA-4203.

Interventions

NameTypeDescription
IMA203BIOLOGICALone-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy
nivolumab plus relatlimabBIOLOGICALin accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
lifileucelBIOLOGICALin accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
nivolumabBIOLOGICALin accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
pembrolizumabBIOLOGICALin accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
ipilimumabBIOLOGICALin accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
DacarbazineDRUGin accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
temozolomideDRUGin accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
paclitaxelDRUGin accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
paclitaxel plus carboplatinDRUGin accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Albumin-Bound PaclitaxelDRUGin accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
IMA203 ProductBIOLOGICALThe cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
IMA203 product- flat doseBIOLOGICALThe cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells
IMA203CD8 ProductBIOLOGICALThe cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
IMADetect®DEVICEIMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials.
mRNA-4203BIOLOGICALmRNA-4203 will be administered starting on Day 15 after IMA203 infusion at the earliest. mRNA-4203 will be given for 12 cycles (28 day cycle length); during Cycle 1 it will be given on Day 1 and Day 15 and in Cycles 2-12 it will be given on Day 1.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites71

Inclusion Criteria: * Pathologically confirmed and documented cutaneous melanoma or mucosal melanoma. CM patients (including acral melanoma and melanoma of unknown primary) and mucosal melanoma patients with unresectable or metastatic disease * Positive for HLA-A\*02:01 or one of its P-group allele...

Countries:United StatesCanadaFranceGermanyNetherlandsUnited Kingdom
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMOct 30, 2026NCT06743126Enrollment: 360 → 450
MEDIUMOct 30, 2026NCT06743126Enrollment: 360 → 450
LOWAug 18, 2026NCT06743126lastUpdatePostDate: changed
LOWAug 18, 2026NCT06743126lastUpdatePostDate: changed

Frequently asked questions about IMA203

What is IMA203?

IMA203 is an investigational cell therapy developed by Immatics N.V. for advanced cancers, including cutaneous melanoma and other refractory solid tumors. It is designed to target PRAME, a protein expressed in multiple tumor types, and is being studied both as monotherapy and in combination with other agents in clinical trials.

What does IMA203 target?

IMA203 targets PRAME, a cancer-associated protein presented on tumor cells. The therapy is designed to direct a T cell response against PRAME-expressing tumors. PRAME is the molecular target underlying the program, which Immatics is developing across melanoma and other refractory solid tumor settings.

Who is developing IMA203?

IMA203 is being developed by Immatics N.V., a biopharmaceutical company listed under the ticker IMTX. Immatics is running the clinical program, including a Phase 3 study in previously treated cutaneous melanoma and earlier-stage studies in solid tumors and in combination with mRNA-4203.

What phase is IMA203 in?

IMA203 is in Phase 3 development. The SUPRAME study, NCT06743126, is a randomized Phase 3 trial comparing IMA203 against investigator's choice of treatment in previously treated, unresectable or metastatic cutaneous melanoma. IMA203 also continues in Phase 1 studies. It has received RMAT designation from the FDA.

What clinical trials is IMA203 in?

IMA203 is being studied in three recruiting trials. NCT06743126 is the Phase 3 SUPRAME study in cutaneous and mucosal melanoma across the United States, Canada, and Europe. NCT03686124 is a Phase 1 study in refractory solid tumors, and NCT06946225 is a Phase 1 study combining IMA203 with mRNA-4203 in cutaneous melanoma and synovial sarcoma.

Is IMA203 the same as the IMA203 product or flat dose?

Yes. IMA203, IMA203 product, and IMA203 product flat dose refer to the same Immatics cell therapy program targeting PRAME. These names appear across the company's clinical trial listings and program descriptions for the melanoma and refractory solid tumor studies.